Brief: Affimed To Collaborate With Genentech To Develop Novel Nk Cell Engager-Based Immunotherapeutics

Affimed NV

27/08/2018 21:23

Aug 27 (Reuters) - Affimed NV  AFMD.O :
    * AFFIMED ANNOUNCES COLLABORATION WITH GENENTECH TO DEVELOP
NOVEL
NK CELL ENGAGER-BASED IMMUNOTHERAPEUTICS FOR MULTIPLE CANCER
TARGETS
    * AFFIMED NV -  TO RECEIVE $96 MILLION UPFRONT AND COMMITTED
FUNDING AND IS ELIGIBLE FOR UP TO AN ADDITIONAL $5.0 BILLION
INCLUDING MILESTONE PAYMENTS
    * AFFIMED NV -  ADDITIONAL $5.0 BILLION CO MAY RECEIVE ALSO
INCLUDES ROYALTIES ON SALES

Source text for Eikon:  ID:nGNX52SmST 
Further company coverage:  AFMD.O 

 ((Reuters.Briefs@thomsonreuters.com;))